Reviews

Why do cancer patients smoke and what can providers do about it?


 

Despite the widespread dissemination of information about the health risks associated with smoking, many cancer patients continue to smoke, which results in a decreased quality of life, an increased probability of cancer recurrence, and a decreased survival time. Efficacious interventions are available to assist cancer patients to quit smoking, yet smoking cessation interventions are often not implemented. This review describes how clinicians, administrators, insurers, and purchasers can encourage a culture of health care in which tobacco cessation interventions are implemented consistent with evidence-based standards of care. Implementing efficacious tobacco cessation interventions can reduce morbidity and mortality among cancer patients...

*Click on the link to the left of this introduction for a PDF of the full article.

Recommended Reading

ASCO 2012: Three Causes for Optimism in Lung Cancer
MDedge Hematology and Oncology
Early Lung Cancer Patients Living Longer After Radiotherapy
MDedge Hematology and Oncology
Prophylactic Cranial Irradiation Fails to Improve NSCLC Survival
MDedge Hematology and Oncology
Experimental Pemetrexed Regimen No Boon to Lung Cancer Survival
MDedge Hematology and Oncology
Crizotinib Changes Practice for Advanced ALK-Positive NSCLC
MDedge Hematology and Oncology
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) (ECLIPSE)
MDedge Hematology and Oncology
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
MDedge Hematology and Oncology
FDA Approves Abraxane for Non-Small Cell Lung Cancer
MDedge Hematology and Oncology
Company for Crizotinib? New ALK Inhibitors Attack Lung Cancer
MDedge Hematology and Oncology
The Cancer Screening Wars
MDedge Hematology and Oncology